Lin BioScience Inc.

Lin BioScience, Inc. is a drug development company focused on therapies for oncology, ophthalmology, and metabolic diseases. Its pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD) and Stargardt disease (STGD1), which is in Phase 3 trials for adolescent STGD1 and in Phase 2 or Phase 3 trials for Dry AMD. Other candidates include LBS-007, a natural non-ATP CDC7 inhibitor for cancer; LBS-002, a first-in-class anti-tubulin for primary and metastatic brain tumors; and LBS-009, an oral therapy for non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.